Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle modification, produces clinically significant and sustained mean body weight reductions of 14–16% in adults without type 2 diabetes and 9.6% in adults with type 2 diabetes.
If you have obesity or overweight with a related health issue (like high blood pressure or diabetes) and lifestyle changes alone haven't worked, talk to your doctor about semaglutide 2.4 mg. It is a once-weekly injection taken alongside a healthy diet and exercise. It is not a substitute for lifestyle changes but helps overcome the body's natural tendency to regain weight. Be aware of potential side effects and that the dose starts low and increases gradually to help your body adjust.
Clinically significant and sustained mean reductions in body weight of 14–16% in participants without type 2 diabetes (T2D) and 9.6% in people with T2D were observed in the phase 3 Semaglutide Treatment Effect in People with obesity (STEP) 1–5 trials...
Why this rating
Based on phase 3 STEP 1-5 trials, which are large, placebo-controlled clinical trials.
Source
Integrating semaglutide into obesity management – a primary care perspective
Janine V. Kyrillos et al. · Postgraduate Medicine · 2022
DOI 10.1080/00325481.2022.2149964
More from this paper
- Semaglutide 2.4 mg improves cardiometabolic risk factors, including blood pressure, lipids, glycated hemoglobin, and C-reactive protein, extending benefits beyond weight loss alone.Strong
- Obesity is a chronic disease characterized by complex abnormalities in body weight regulation, and weight-related stigmatization is a key barrier to effective care.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →